Zomedica Reports Q1 2025 Growth Amid Strategic Expansion

Zomedica Pharma ( (ZOMDF) ) has released its Q1 earnings. Here is a breakdown of the information Zomedica Pharma presented to its investors.

Zomedica Corp., a veterinary health company, specializes in point-of-care diagnostic and therapeutic products for equine and companion animals, aiming to enhance animal healthcare with innovative solutions. In its first quarter of 2025, Zomedica reported a revenue of $6.5 million, marking a 4% increase from the previous year, alongside a robust gross margin of 68%. The company attributed its financial performance to the strong demand for its PulseVet and TRUFORMA product lines and the successful launch of its VETIGEL product line.

Key financial highlights include an 8% increase in therapeutic device segment revenue, driven by PulseVet and Assisi products, and a 13% growth in consumable revenues. However, diagnostics segment revenue saw a decline of 25%, primarily due to the absence of large initial distribution orders for VetGuardian products that were present in the previous year. Despite a non-cash impairment charge of $55.8 million, Zomedica maintained a liquidity position of $65 million.

Operating expenses, excluding the impairment charge, were reduced by 9% compared to the first quarter of 2024, reflecting cost management efforts. The company also reported an adjusted non-GAAP EBITDA loss of $5.7 million, slightly higher than the previous year’s loss of $5.3 million, indicating ongoing investments in research and development and sales expansion.

Looking ahead, Zomedica’s management remains optimistic about its growth prospects, supported by a strong balance sheet and strategic initiatives aimed at accelerating the global adoption of its innovative product portfolio. The company is poised to leverage its momentum to enhance its market presence and drive future revenue growth.